These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10992303)

  • 1. Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study.
    Benner T; Reimer P; Erb G; Schuierer G; Heiland S; Fischer C; Geens V; Sartor K; Forsting M
    J Magn Reson Imaging; 2000 Sep; 12(3):371-80. PubMed ID: 10992303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T.
    Essig M; Lodemann KP; Le-Huu M; Brüning R; Kirchin M; Reith W
    Invest Radiol; 2006 Mar; 41(3):256-63. PubMed ID: 16481908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic contrast-enhanced T2*-weighted MRI in patients with cerebrovascular disease.
    Reith W; Heiland S; Erb G; Benner T; Forsting M; Sartor K
    Neuroradiology; 1997 Apr; 39(4):250-7. PubMed ID: 9144671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers].
    Essig M; Lodemann KP; LeHuu M; Schönberg SO; Hübener M; Van Kaick G
    Radiologe; 2002 Nov; 42(11):909-15. PubMed ID: 12458444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T.
    Thilmann O; Larsson EM; Björkman-Burtscher IM; Ståhlberg F; Wirestam R
    J Magn Reson Imaging; 2005 Nov; 22(5):597-604. PubMed ID: 16200539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional dynamic susceptibility-weighted perfusion MR imaging at 3.0 T: feasibility and contrast agent dose.
    Manka C; Träber F; Gieseke J; Schild HH; Kuhl CK
    Radiology; 2005 Mar; 234(3):869-77. PubMed ID: 15665227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carotid MR angiography: phase II study of safety and efficacy for MS-325.
    Bluemke DA; Stillman AE; Bis KG; Grist TM; Baum RA; D'Agostino R; Malden ES; Pierro JA; Yucel EK
    Radiology; 2001 Apr; 219(1):114-22. PubMed ID: 11274545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential dynamic gadolinium magnetic resonance perfusion-weighted imaging: effects on transit time and cerebral blood volume measurements.
    Griffiths PD; Pandya H; Wilkinson ID; Hoggard N
    Acta Radiol; 2006 Dec; 47(10):1079-84. PubMed ID: 17135012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perfusion-weighted magnetic resonance imaging in patients with carotid artery disease before and after carotid endarterectomy.
    Doerfler A; Eckstein HH; Eichbaum M; Heiland S; Benner T; Allenberg JR; Forsting M
    J Vasc Surg; 2001 Oct; 34(4):587-93. PubMed ID: 11668309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography.
    Goyen M; Lauenstein TC; Herborn CU; Debatin JF; Bosk S; Ruehm SG
    J Magn Reson Imaging; 2001 Nov; 14(5):602-7. PubMed ID: 11747013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of blood-brain barrier disruption on MR images of cats with acute cerebral infarction: value of administering a high dose of contrast material.
    Runge VM; Kirsch JE; Wells JW; Dunworth JN; Woolfolk CE
    AJR Am J Roentgenol; 1994 Feb; 162(2):431-5. PubMed ID: 8310940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial.
    Rubin DL; Desser TS; Semelka R; Brown J; Nghiem HV; Stevens WR; Bluemke D; Nelson R; Fultz P; Reimer P; Ho V; Kristy RM; Pierro JA
    J Magn Reson Imaging; 1999 Feb; 9(2):240-50. PubMed ID: 10077020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.
    Staks T; Schuhmann-Giampieri G; Frenzel T; Weinmann HJ; Lange L; Platzek J
    Invest Radiol; 1994 Jul; 29(7):709-15. PubMed ID: 7960618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [MR tomographic studies of the cerebral circulation: the methodological principles and initial clinical experiences with T2*-weighted gradient-echo sequences and CM administration as a bolus].
    Gückel F; Wentz KU; Brix G; Jaschke W; Röther J; Loose R; Deimling M; Georgi M
    Rofo; 1992 Mar; 156(3):212-7. PubMed ID: 1550915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
    Runge VM; Parker JR; Donovan M
    Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a high relaxivity contrast agent administered at half dose in dynamic susceptibility contrast MRI of brain gliomas.
    Crisi G; Filice S; Erb G; Bozzetti F
    J Magn Reson Imaging; 2017 Feb; 45(2):500-506. PubMed ID: 27373976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the longitudinal relaxation rate of blood after gadobenate dimeglumine administration: sequence optimization, dynamic acquisition, and clinical impact for contrast-enhanced MR angiography of the carotid arteries.
    Neira C; Anzidei M; Napoli A; Kirchin MA; Cavallo Marincola B; Zaccagna F; Catalano C; Passariello R; Tedoldi F
    Invest Radiol; 2011 Dec; 46(12):774-82. PubMed ID: 21730871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels.
    Fink C; Puderbach M; Ley S; Plathow C; Bock M; Zuna I; Kauczor HU
    Invest Radiol; 2004 Mar; 39(3):143-8. PubMed ID: 15076006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.